Inventiva S.A. (LON:0RNK)
2.680
-0.100 (-3.60%)
Mar 13, 2025, 4:28 PM BST
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M EUR
Revenue Growth
-12.56%
P/S Ratio
n/a
Revenue / Employee
156.71K EUR
Employees
123
Market Cap
215.15M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 483.31M |
Genus | 671.60M |
Inventiva News
- 15 days ago - Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment - GlobeNewsWire
- 21 days ago - Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial - GlobeNewsWire
- 4 weeks ago - Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - GlobeNewsWire
- 6 weeks ago - Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology - GlobeNewsWire
- 6 weeks ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 7 weeks ago - Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 - GlobeNewsWire
- 3 months ago - Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Inventiva secures €21.4 million - Seeking Alpha